Claims

1. A blister pack containing at least one tablet comprising:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; and

at least one disintegrating excipient;

wherein the tablet has a hardness of from 50 to 150N and a disintegration time of less than 3 minutes;

wherein the at least one disintegrating excipient comprises mannitol, xylitol, anhydrous dibasic calcium phosphate, crospovidone and microcrystalline cellulose.

2. The blister pack according to Claim 1, wherein the tablet has a disintegration time of less than about 60 seconds.

3. The blister pack according to claim 1 or claim 2, wherein the at least one disintegrating excipient is a disintegrating excipient pre-mix that is present in an amount ranging from 50% to 80% by weight of the tablet.

4. The blister pack according to any one of the preceding claims, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is present in an amount of from 10 to 18% by weight of the tablet.

5. The blister pack according to any one of the preceding claims, wherein the tablet comprises 60 mg or 90 mg of (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.

6. The blister pack according to Claim 5, wherein the tablet comprises about 90 mg of (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol.

7. The blister pack according to any one of the preceding claims, wherein the tablet has a hardness of from 55 to 90N.

8. The blister pack according to any one of the preceding claims, wherein the tablet further comprises at least one anti-caking agent.

9. The blister pack according to Claim 8, wherein the at least one anti-caking agent is present in an amount of from 0.5 to 1% by weight of the tablet.

10. The blister pack according to any one of the preceding claims, wherein the tablet is obtainable by a process comprising wet granulation of:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol; and

an anti-caking agent.

11. The blister pack according to Claim 10, wherein the wet granulation process involves the wet granulation of a mixture comprising (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol in an amount of at least about 35% of by weight of the dry ingredients in the mixture.

12. The blister pack according to Claim 10 or Claim 11, wherein the wet granulation process involves the wet granulation of a mixture comprising (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol in an amount of up to about 70% by weight of the dry ingredients in the mixture.

13. The blister pack according to any one of Claims 10 to 12, wherein the mixture used in the wet granulation process comprises said anti-caking agent in an amount ranging from 0.1 to 1% by weight of the dry ingredients in the mixture.

14. The blister pack according to any one of Claims 10 to 13, wherein the product of the wet granulation process comprises granules having a D (v, 0.9) value of less than about 1600 µm.

15. The blister pack according to any one of Claims 10 to 14, wherein, after completion of the wet granulation step, the product is mixed with a second amount of an anti-caking agent or a glidant.

16. The blister pack according to Claim 15 wherein the second amount of an anti-caking agent or the glidant is present at from 0.2 to 0.6%, preferably from 0.3 to 0.6%, by weight of the tablet.

17. The blister pack according to any one of Claims 10 to 16, wherein the tablet is obtainable by a process comprising wet granulation of:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol;

an anti-caking agent; and

a binder.

18. The blister pack according to Claim 17, wherein the binder is present in the wet granulation mixture at an amount ranging from 2 to 6%, preferably from 3 to 6%, by weight of the dry ingredients in the mixture.

19. The blister pack according to any one of the preceding claims, wherein the tablet comprises one or more lubricants.

20. The blister pack according to Claim 19, wherein the lubricant is present in an amount of from 1 to 2% by weight of the tablet.

21. The blister pack according to any one of the preceding claims, wherein the tablet comprises:

(1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol at from 10 to 18% by weight of the tablet;

hydroxypropyl cellulose at from 0.9 to 2% by weight of the tablet;

colloidal anhydrous silica at from 0.5 to 1% by weight of the tablet;

mannitol at from 47 to 67% by weight of the tablet;

xylitol at from 2.5 to 4% by weight of the tablet;

anhydrous dibasic calcium phosphate at from 2 to 3.5% by weight of the tablet;

microcrystalline cellulose at from 9 to 15% by weight of the tablet;

crospovidone at from 5 to 9% by weight of the tablet; and
sodium stearyl fumarate at from 1 to 2% by weight of the tablet.

22. The blister pack according to any of the preceding claims, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol has a D (v, 0.9) particle size distribution of from 5 µm to 50 µm.

23. The blister pack according to any of the preceding claims, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of polymorph II.

24. The blister pack according to any of Claims 1 to 22, wherein the (1*S*,2*S*,3*R*,5*S*)-3-[7-{[(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylthio)-3*H*-[1,2,3]-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol is substantially present in the form of polymorph III.

25. A blister pack containing at least one tablet as defined in any one of Claims 1 to 24, wherein the blister pack comprises a blistered base sheet comprising one or more cavities, and a lidding sheet bonded to the base sheet, wherein the edge of the blister pack comprises at least one break in the blistered base sheet and the lidding sheet such that the blister pack is tearable at the break to expose the cavity.

26. The blister pack according to any one of Claims 1 to 25, wherein the at least one break is positioned adjacent to one of the cavities.

27. The blister pack according to any one of Claims 1 to 26, wherein the break separates two regions of the edge of the blister pack which are capable of being gripped and pulled apart to tear the blistered base sheet and the lidding sheet.

28. The blister pack according to any one of Claims 1 to 27, wherein the break is a cleft or an incision.

29. The blister pack according to any one of Claims 1 to 28, wherein the innermost part of the break is at least 3 mm from the nearest cavity.

30. The blister pack according to any one of Claims 1 to 29, wherein the blister pack comprises at least one break positioned adjacent to each cavity.

31. The blister pack according to any one of Claims 1 to 30, wherein the blistered base sheet comprises an aluminium layer or a polymer layer.

32. The blister pack according to Claim 31, wherein the blistered base sheet has a thickness of 100 µm to 200 µm.

33. The blister pack according to any one of Claims 1 to 32, wherein the lidding sheet comprises an aluminium layer.

34. The blister pack according to Claim 33, wherein the lidding sheet has a thickness of 15 µm to 60 µm.

35. The blister pack according to any one of Claims 1 to 34, wherein the blister pack comprises at least two cavities and further comprises a perforated region which forms a tear path passing between two of said cavities.